Emergent snags opioid drug in $735M buyout deal; Germany frets about post-Brexit disruption in drug market

Emergent BioSolutions has struck a $735 million deal to acquire Adapt, which markets an opioid overdose drug called Narcan. Emergent is paying $635 million of that upfront. The buyout comes as the US grapples with an opioid crisis that has been driving a considerable amount of government contracting.

Reuters reports that Germany wants its drugmakers to examine the possibility of any new drug shortages that may be created by Brexit. The UK’s departure from the EU has raised repeated alarms about changes that could roil the industry — particularly if the withdrawal comes without a deal in place to govern the move.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->